We are excited to announce a cutting-edge development from one of our portfolio companies, Belluscura. As it has been known, the primary cause of death of the COVID-19 is respiratory failure, and this new technology that Belluscura has patented provides supplemental oxygen to the patient in a way that bypasses the lungs.

We are happy to be positively contributing to this pandemic and situation that we are currently living and it is crucial to see the importance of technology and innovation for the betterment of society.

Read more about this on UK Investor Magazine.